{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T18:59:28Z","timestamp":1789153168086,"version":"build-2803163510"},"reference-count":32,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Clin Appl Thromb Hemost"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hemophilia A and B are X-linked recessive bleeding disorders caused by deficiencies of coagulation factors VIII and IX, respectively. These conditions lead to spontaneous bleeding, joint damage, inhibitor development, and the burden of frequent intravenous infusions. Concizumab, a monoclonal antibody targeting tissue factor pathway inhibitor (TFPI), is a novel non-factor therapy that enhances thrombin generation. This systematic review evaluates the efficacy and safety of concizumab prophylaxis in patients with hemophilia A and B.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This systematic review was conducted in accordance with PRISMA guidelines. Randomized controlled trials (RCTs) assessing the use of concizumab in hemophilia A or B were identified through a comprehensive search of electronic databases. Outcomes of interest included annualized bleeding rate (ABR), thrombin generation, bleeding episodes, immunogenicity, and adverse events. The Cochrane Risk of Bias Tool 2.0 was used for quality assessment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Five studies were included. Concizumab prophylaxis was associated with a notable reduction in ABR, with reported decreases from 9.4 to 1.3 episodes\/year and from 19.6 to 2.9 episodes\/year in hemophilia A, and from 14.9 to 1.6 episodes\/year in hemophilia B. Thrombin generation increased in a dose-dependent manner and stabilized by week 24. Across all studies, bleeding episodes were significantly reduced. Adverse events were primarily mild to moderate. No thromboembolic events were reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Concizumab appears to be an effective and safe prophylactic treatment for patients with hemophilia A and B, demonstrating consistent reductions in bleeding rates and enhanced thrombin generation. Further long-term studies are warranted to establish its sustained safety and efficacy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10760296251342968","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T19:32:28Z","timestamp":1747251148000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluating the Safety and Efficacy of Concizumab in Hemophilia A\/B Patients: A Systematic Review"],"prefix":"10.1177","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7183-1022","authenticated-orcid":false,"given":"Erum","family":"Siddiqui","sequence":"first","affiliation":[{"name":"Department of Medicine, Jinnah Sindh Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3413-2752","authenticated-orcid":false,"given":"Maliha","family":"Khalid","sequence":"additional","affiliation":[{"name":"Department of Medicine, Jinnah Sindh Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4228-6476","authenticated-orcid":false,"given":"Muhammad Saad","family":"Khan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Jinnah Sindh Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6211-7522","authenticated-orcid":false,"given":"Kanza","family":"Farhan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Jinnah Sindh Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2353-0276","authenticated-orcid":false,"given":"Muhammad Mohsin","family":"Khan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Jinnah Sindh Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3283-1982","authenticated-orcid":false,"given":"Aminath","family":"Waafira","sequence":"additional","affiliation":[{"name":"The Maldives National University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,5,14]]},"reference":[{"issue":"2","key":"e_1_3_2_2_2","first-page":"178","article-title":"The modern treatment of haemophilia: A narrative review","volume":"11","author":"Franchini M","year":"2013","unstructured":"Franchini M. The modern treatment of haemophilia: A narrative review. Blood Transfus = Trasfusione del Sangue [Internet]. 2013;11(2):178\u2010182. Available from https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3626468\/.","journal-title":"Blood Transfus = Trasfusione del Sangue [Internet]"},{"key":"e_1_3_2_3_2","article-title":"Foundations of hemophilia and epidemiology","volume":"34","author":"Quintana Paris L","year":"2023","unstructured":"Quintana Paris L. Foundations of hemophilia and epidemiology. Blood Coagul Fibrinolysis [Internet]. 2023;34:S35. Available from https:\/\/journals.lww.com\/bloodcoagulation\/fulltext\/2023\/06001\/foundations_of_hemophilia_and_epidemiology.11.aspx.","journal-title":"Blood Coagul Fibrinolysis [Internet]"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08919.x"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S6885"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13145"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1517\/14728214.10.1.173"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0029-1245113"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1177\/2042098611415566"},{"issue":"5","key":"e_1_3_2_10_2","first-page":"457","article-title":"Non-factor replacement therapy for haemophilia: A current update","volume":"16","author":"Franchini M","year":"2018","unstructured":"Franchini M, Mannucci PM. Non-factor replacement therapy for haemophilia: A current update. Blood Transfus [Internet]. 2018;16(5):457\u2010461. Available from https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6125230\/.","journal-title":"Blood Transfus [Internet]"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001140"},{"key":"e_1_3_2_12_2","article-title":"Anti-tissue factor pathway inhibitor (TFPI) therapy: a novel approach to the treatment of haemophilia","author":"Chowdary P","year":"2018","unstructured":"Chowdary P. Anti-tissue factor pathway inhibitor (TFPI) therapy: a novel approach to the treatment of haemophilia. Int J Hematol. 2018.","journal-title":"Int J Hematol."},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0922-6"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-166522"},{"key":"e_1_3_2_15_2","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. Br Med J. 2021;372:n71. doi: https:\/\/doi.org\/10.1136\/bmj.n71. PMID: 33782057; PMCID: PMC8005924.","journal-title":"Br Med J."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12864"},{"issue":"11","key":"e_1_3_2_17_2","first-page":"2184","article-title":"A randomized trial of safety, pharmacokinetics and pharmacodynamics of concizumab in people with hemophilia A","volume":"16","author":"Eichler HJ","year":"2018","unstructured":"Eichler HJ, Angchaisuksiri P, Kavakli K, et al. A randomized trial of safety, pharmacokinetics and pharmacodynamics of concizumab in people with hemophilia A. JTH. 2018;16(11):2184\u20102195.","journal-title":"JTH"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2216455"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(24)00307-7"},{"key":"e_1_3_2_20_2","unstructured":"Risk of bias tools - Current version of RoB 2. sites.google.com. https:\/\/sites.google.com\/site\/riskofbiastool\/welcome\/rob-2-0-tool\/current-version-of-rob-2?authuser=0"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtha.2024.05.020"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.htct.2023.09.854"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S242219"},{"issue":"1","key":"e_1_3_2_24_2","first-page":"3","article-title":"Safety first: Tracking adverse events associated with new therapies for people with hemophilia","volume":"19","author":"Recht M","year":"2020","unstructured":"Recht M. Safety first: Tracking adverse events associated with new therapies for people with hemophilia. J Thromb Haemostasis. 2020;19(S1):3\u20105.","journal-title":"J Thromb Haemostasis."},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2019.1626370"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2018.1531701"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2023.2243213"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1703068"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1511769"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1177\/2040620718799997"},{"issue":"6","key":"e_1_3_2_31_2","article-title":"Nonfactor therapies for hemophilia","volume":"7","author":"Young G","year":"2023","unstructured":"Young G. Nonfactor therapies for hemophilia. HemaSphere [Internet]. 2023;7(6):e911\u2010e911. Available from https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC10247213\/.","journal-title":"HemaSphere [Internet]"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2019.100618"},{"issue":"2","key":"e_1_3_2_33_2","article-title":"Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B","volume":"2","author":"Olasupo OO","year":"2024","unstructured":"Olasupo OO, Noronha N, Lowe MS, Ansel D, Bhatt M, Matino D. Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B. Cochrane Database Syst Rev. 2024;2(2):CD014544. doi:https:\/\/doi.org\/10.1002\/14651858.CD014544.pub2","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Clinical and Applied Thrombosis\/Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10760296251342968","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10760296251342968","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10760296251342968","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:05:14Z","timestamp":1777385114000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10760296251342968"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,14]]},"references-count":32,"alternative-id":["10.1177\/10760296251342968"],"URL":"https:\/\/doi.org\/10.1177\/10760296251342968","relation":{},"ISSN":["1076-0296","1938-2723"],"issn-type":[{"value":"1076-0296","type":"print"},{"value":"1938-2723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,14]]},"article-number":"10760296251342968"}}